Objective:To investigate the effects of mirror therapy(MT)combined with kinesio taping(KT)on persistent pain and quality of life after breast cancer treatment.Method:Patients with persistent pain after breast cancer treatment were recruited from January 2022 to Decem-ber 2022 from Department of Rehabilitation Medicine,Jing'an District Central Hospital of Shanghai.A total of 43 patients were randomized into the combination group(MT+KT,n=22)and the KT group(n=21).Patients in both groups received conventional physical rehabilitation therapy.Additionally,the KT group received kinesio tap-ing and sham mirror therapy,while the combined group received kinesio taping and mirror therapy.Before treat-ment and after 4 weeks of treatment,numerical rating scales(NRSs)was used to evaluate pain,bilateral grip strength was measured using J-Tech grip strength device,shoulder range of motion(ROM)was measured using the goniometer,and quality of life was measured using the short form-36(SF-36)Result:There were no significant differences in NRSs score,grip strength difference,shoulder flexion and ab-duction difference,and SF-36 score between two groups before treatment(P＞0.05).After 4 weeks of interven-tion,the NRSs score,shoulder flexion and shoulder abduction of the combined group were significantly im-proved compared with those before treatment(P＜0.05).The NRSs score,shoulder flexion and shoulder abduc-tion in group KT were significantly improved compared with those before treatment(P＜0.05).Comparison be-tween groups showed that NRSs score of combined group was significantly lower than that of group KT(P=0.001),although grip strength,shoulder flexion and abduction of combined group were improved compared with group KT,but the difference was no statistically significant(P＞0.05).After 4 weeks of intervention,the scores of physiological function,general health and emotional function of SF-36 in combination group were significantly higher than those in group KT(P＜0.05).Conclusion:Mirror therapy combined with kinesio taping can effectively improve the persistent pain and spe-cific aspects of the quality of life in patients after breast cancer treatment.

Objective To explore the targets and mechanisms of Tongguanteng Injection in inhibiting the proliferation and migration of cervical cancer.Methods The biological activity of Tongguanteng Injection in inhibiting human cervical cancer SiHa cells was determined by MTT method.Detecting the effect of Tongguanteng Injection on SiHa cell migration through wound healing assay.Using network pharmacology to collect the key targets for treating cervical cancer,and perform molecular docking and enrichment analysis on the targets.Immunohistochemistry and Western blot were used to detect the key proteins to validate the network pharmacology predictions.Result Tongguanteng Injection significantly inhibited the proliferation and migration in a dose-dependent manner in human cervical cancer SiHa cells.Based on the main active ingredients of Marsdenia tenacissima,81 therapeutic targets for cervical cancer were obtained,which may treat cervical cancer by affecting key proteins such as FGF2,MAPK1,and MAPK3.Immunohistochemical results indicated that FGF2,MAPK1 and MAPK3 were expressed in cervical cancer tissues.The western bolt assays showed that Tongguanteng Injection could significantly reduce the FGF2 protein expression.Meanwhile,the MAPK1 and MAPK3 protein expressions were significantly increased.Conclusion Tongguanteng Injection may regulate the FGF2,MAPK1 and MAPK3,effectively impede the proliferation and migration of cervical cancer.

Objective:To analyze the clinical features and prognosis of acute B lymphoblastic leukemia (B-ALL) children carrying a TCF3: : PBX1 fusion gene and to evaluate the prognostic value of this gene.Methods:Retrospective cohort study.A total of 2 164 B-ALL children aged 0-18 years diagnosed and treated at 19 pediatric centers from October 2016 to June 2022 were enrolled.They were divided into the positive group and the negative group according to whether they carried a TCF3: : PBX1 fusion gene.The clinical characteristics, treatment response, adverse reactions, and prognosis of the 2 groups of patients were analyzed.The rank sum and Kruskal-Wallis tests were used to compare two and more than two groups of numerical variables, respectively.Fisher′s exact test was used to compare categorical variables.Results:Among the 2 164 patients, 116 (5.4%) were TCF3: : PBX1 positive, of which 70 patients were female, accounting for 60.3%.There were 840 female patients in the TCF3: : PBX1-negative group, accounting for 41.0%.There was a significant difference in the ratio of females between the TCF3: : PBX1-positive and TCF3: : PBX1-negative groups ( P<0.001).No significant difference was observed in age of onset between the two groups( P>0.05).The proportion of bone marrow naive cells [54.00 (14.00, 76.50)% vs.29.00 (3.00, 68.00)%], white blood cell counts [25.30 (10.46, 60.94)×10 9/L vs.9.03 (4.38, 30.73)×10 9/L] and hemoglobin counts [82.00(63.00, 101.00) g/L vs.74.00(60.00, 90.00) g/L] in the TCF3: : PBX1-positive group were significantly higher than those in the negative group at the onset (all P<0.05).In terms of treatment response, the proportion of peripheral blood naive cells on Day 8 in the TCF3: : PBX1-positive group was significantly higher than that in the negative group [2.00 (0, 9.00)% vs.0 (0, 2.00)%, P<0.001].The proportion of minimal residual disease <0.1% on Day 15 in the TCF3: : PBX1-positive group was significantly higher than that in the negative group ( P=0.038).There were no significant differences in cumulative recurrence rate, treatment-related mortality (TRM), and overall survival (OS) between the TCF3: : PBX1-positive group and TCF3: : PBX1-negative group (all P>0.05).The cumulative recurrence risk of TCF3: : PBX1-positive patients was 9.646 times higher than that of ETV6: : RUNX1-positive patients with better prognosis( HR=9.646, 95% CI: 1.026-90.700, P=0.047).There were no significant differences in TRM and OS between TCF3: : PBX1-positive and ETV6: : RUNX1-positive patients (all P>0.05).A significant enrichment of PAX5 mutations was detected in TCF3: : PBX1-positive patients.Among the 7 high-risk TCF3: : PBX1-positive patients in a single center, 4 patients had PAX5 mutations, and this proportion was significantly higher than that in other patients ( P<0.001). Conclusions:B-ALL children carrying a TCF3: : PBX1 fusion gene have a high remission rate and good long-term prognosis after intensive chemotherapy.It is suggesting that TCF3: : PBX1-positive B-ALL patients should be rated at intermediate risk to receive intensive chemotherapy.

Objective To explore the targets and mechanisms of Tongguanteng Injection in inhibiting the proliferation and migration of cervical cancer.Methods The biological activity of Tongguanteng Injection in inhibiting human cervical cancer SiHa cells was determined by MTT method.Detecting the effect of Tongguanteng Injection on SiHa cell migration through wound healing assay.Using network pharmacology to collect the key targets for treating cervical cancer,and perform molecular docking and enrichment analysis on the targets.Immunohistochemistry and Western blot were used to detect the key proteins to validate the network pharmacology predictions.Result Tongguanteng Injection significantly inhibited the proliferation and migration in a dose-dependent manner in human cervical cancer SiHa cells.Based on the main active ingredients of Marsdenia tenacissima,81 therapeutic targets for cervical cancer were obtained,which may treat cervical cancer by affecting key proteins such as FGF2,MAPK1,and MAPK3.Immunohistochemical results indicated that FGF2,MAPK1 and MAPK3 were expressed in cervical cancer tissues.The western bolt assays showed that Tongguanteng Injection could significantly reduce the FGF2 protein expression.Meanwhile,the MAPK1 and MAPK3 protein expressions were significantly increased.Conclusion Tongguanteng Injection may regulate the FGF2,MAPK1 and MAPK3,effectively impede the proliferation and migration of cervical cancer.

Objective:To investigate the effects of mirror therapy(MT)combined with kinesio taping(KT)on persistent pain and quality of life after breast cancer treatment.Method:Patients with persistent pain after breast cancer treatment were recruited from January 2022 to Decem-ber 2022 from Department of Rehabilitation Medicine,Jing'an District Central Hospital of Shanghai.A total of 43 patients were randomized into the combination group(MT+KT,n=22)and the KT group(n=21).Patients in both groups received conventional physical rehabilitation therapy.Additionally,the KT group received kinesio tap-ing and sham mirror therapy,while the combined group received kinesio taping and mirror therapy.Before treat-ment and after 4 weeks of treatment,numerical rating scales(NRSs)was used to evaluate pain,bilateral grip strength was measured using J-Tech grip strength device,shoulder range of motion(ROM)was measured using the goniometer,and quality of life was measured using the short form-36(SF-36)Result:There were no significant differences in NRSs score,grip strength difference,shoulder flexion and ab-duction difference,and SF-36 score between two groups before treatment(P＞0.05).After 4 weeks of interven-tion,the NRSs score,shoulder flexion and shoulder abduction of the combined group were significantly im-proved compared with those before treatment(P＜0.05).The NRSs score,shoulder flexion and shoulder abduc-tion in group KT were significantly improved compared with those before treatment(P＜0.05).Comparison be-tween groups showed that NRSs score of combined group was significantly lower than that of group KT(P=0.001),although grip strength,shoulder flexion and abduction of combined group were improved compared with group KT,but the difference was no statistically significant(P＞0.05).After 4 weeks of intervention,the scores of physiological function,general health and emotional function of SF-36 in combination group were significantly higher than those in group KT(P＜0.05).Conclusion:Mirror therapy combined with kinesio taping can effectively improve the persistent pain and spe-cific aspects of the quality of life in patients after breast cancer treatment.

Objective:To analyze the clinical features and prognosis of acute B lymphoblastic leukemia (B-ALL) children carrying a TCF3: : PBX1 fusion gene and to evaluate the prognostic value of this gene.Methods:Retrospective cohort study.A total of 2 164 B-ALL children aged 0-18 years diagnosed and treated at 19 pediatric centers from October 2016 to June 2022 were enrolled.They were divided into the positive group and the negative group according to whether they carried a TCF3: : PBX1 fusion gene.The clinical characteristics, treatment response, adverse reactions, and prognosis of the 2 groups of patients were analyzed.The rank sum and Kruskal-Wallis tests were used to compare two and more than two groups of numerical variables, respectively.Fisher′s exact test was used to compare categorical variables.Results:Among the 2 164 patients, 116 (5.4%) were TCF3: : PBX1 positive, of which 70 patients were female, accounting for 60.3%.There were 840 female patients in the TCF3: : PBX1-negative group, accounting for 41.0%.There was a significant difference in the ratio of females between the TCF3: : PBX1-positive and TCF3: : PBX1-negative groups ( P<0.001).No significant difference was observed in age of onset between the two groups( P>0.05).The proportion of bone marrow naive cells [54.00 (14.00, 76.50)% vs.29.00 (3.00, 68.00)%], white blood cell counts [25.30 (10.46, 60.94)×10 9/L vs.9.03 (4.38, 30.73)×10 9/L] and hemoglobin counts [82.00(63.00, 101.00) g/L vs.74.00(60.00, 90.00) g/L] in the TCF3: : PBX1-positive group were significantly higher than those in the negative group at the onset (all P<0.05).In terms of treatment response, the proportion of peripheral blood naive cells on Day 8 in the TCF3: : PBX1-positive group was significantly higher than that in the negative group [2.00 (0, 9.00)% vs.0 (0, 2.00)%, P<0.001].The proportion of minimal residual disease <0.1% on Day 15 in the TCF3: : PBX1-positive group was significantly higher than that in the negative group ( P=0.038).There were no significant differences in cumulative recurrence rate, treatment-related mortality (TRM), and overall survival (OS) between the TCF3: : PBX1-positive group and TCF3: : PBX1-negative group (all P>0.05).The cumulative recurrence risk of TCF3: : PBX1-positive patients was 9.646 times higher than that of ETV6: : RUNX1-positive patients with better prognosis( HR=9.646, 95% CI: 1.026-90.700, P=0.047).There were no significant differences in TRM and OS between TCF3: : PBX1-positive and ETV6: : RUNX1-positive patients (all P>0.05).A significant enrichment of PAX5 mutations was detected in TCF3: : PBX1-positive patients.Among the 7 high-risk TCF3: : PBX1-positive patients in a single center, 4 patients had PAX5 mutations, and this proportion was significantly higher than that in other patients ( P<0.001). Conclusions:B-ALL children carrying a TCF3: : PBX1 fusion gene have a high remission rate and good long-term prognosis after intensive chemotherapy.It is suggesting that TCF3: : PBX1-positive B-ALL patients should be rated at intermediate risk to receive intensive chemotherapy.

Objective:To investigate the effect and related mechanism of Marsdenia tenacissima combined with XELOX solution on disulfide apoptosis in human colorectal cancer HCT116 cells.Methods:The human colorectal cancer HCT116 cells were cultured in vitro and treated with different concentrations of capecitabine (0, 0.3, 0.6, 1.2, 2.4, 4.8 μg/ml), oxaliplatin (0, 10, 20, 40, 80, 160 μg/ml), Marsdenia tenacissima (0, 15, 30, 60, 120, 240 mg/ml), and the glucose inhibitor BAY-876 (0, 4, 8, 16, 32, 64 μg/ml), respectively. Furthermore, the HCT116 cells were pre-treated with 25 μg/ml of BAY-876, followed by exposure to the specified concentrations of each drug group. HCT116 cells were divided into the following groups: negative control group (no treatment), capecitabine group (4.0 μg/ml), oxaliplatin group (90 μg/ml), Marsdenia tenacissima group (140 mg/ml), XELOX solution group (4.0 μg/ml capecitabine+90 μg/ml oxaliplatin), and Marsdenia tenacissima combined with XELOX solution group (140 mg/ml Marsdenia tenacissima+4.0 μg/ml capecitabine+90 μg/ml oxaliplatin). BAY-876 treatment groups refer to the groups which the glucose inhibitor BAY-876 25 μg/ml was added to each of the above groups. The cell proliferation was assessed using the MTT assay. Apoptosis was determined through Annexin Ⅴ-FITC/PI double staining. The concentration of glucose was quantified using the o-toluidine method. NADPH levels were measured by colorimetry. Cystine uptake fluorescence assay was utilized to quantify the fluorescence intensity of cystine, and cysteine content was determined using cysteine colorimetry. Results:After 0, 0.3, 0.6, 1.2, 2.4, 4.8 μg/ml concentration of capecitabine, 0, 10, 20, 40, 80, 160 μg/ml concentration of oxaliplatin, 0, 4, 8, 16, 32, 64 μg/ml concentration of BAY-876, and after pre-treatment with 25 μg/ml glucose inhibitor BAY-876, HCT116 cells were treated with the above drugs and concentrations, there were statistically significant differences in cell survival rate ( F=644.60, P<0.001; F=417.30, P<0.001; F=1 028.00, P<0.001; F=1 066.00, P<0.001; F=847.70, P<0.001), and with the increase of each drug concentration, the activity of HCT116 cells decreased gradually (all P<0.05). After 0, 15, 30, 60, 120, 240 mg/ml concentration of Marsdenia tenacissima, and after pre-treatment with 25 μg/ml glucose inhibitor BAY-876, HCT116 cells were treated with the above drugs, there were statistically significant differences in cell survival rate ( F=107.50, P<0.001; F=619.70, P<0.001), and with the increase of drug concentration, the activity of HCT116 cells increased first and then decreased (all P<0.05). Annexin Ⅴ-FITC/PI staining showed that the intensity of green, red and yellow fluorescence was weaker in the negative control group. The expression of green fluorescence and red fluorescence was enhanced in each drug group. In capecitabine group, the red fluorescence and yellow fluorescence were larger. The proportion of green fluorescence in oxaliplatin group and Marsdenia tenacissima group was smaller. The proportion of green fluorescence and yellow fluorescence in XELOX solution group was higher than that in capecitabine group and oxaliplatin group. Marsdenia tenacissima combined with XELOX solution group had the highest proportion of green and red fluorescence. After pre-treatment with the glucose inhibitor BAY-876, the green and yellow fluorescence of the cells in each group increased significantly. The green and yellow fluorescence of capecitabine group and oxaliplatin group increased significantly. The fluorescence of XELOX solution group was significantly higher than that of capecitabine group and oxaliplatin group. In Marsdenia tenacissima combined with XELOX solution group, the proportion of fluorescence expressing three colors was the largest. In the negative control group, capecitabine group, oxaliplatin group, Marsdenia tenacissima group, XELOX solution group, Marsdenia tenacissima combined with XELOX solution group, and the groups after BAY-876 pre-treatment, the glucose concentration of HCT116 was (19.91±0.13), (22.82±0.88), (11.87±0.14), (17.93±0.14), (10.53±0.10), (7.56±0.08), (11.44±0.10), (11.73±0.72), (8.98±0.40), (14.25±0.33), (6.77±1.50), and (1.56±0.17) μg/ml, respectively, with statistically significant differences ( F=762.60, P<0.001; F=118.80, P<0.001). Compared with the untreated groups, the intracellular glucose concentration of HCT116 cells treated with BAY-876 was significantly decreased ( t=86.50, P<0.001; t=16.90, P<0.001; t=11.83, P<0.001; t=17.79, P<0.001; t=4.35, P=0.012; t=54.34, P<0.001). NADPH levels in each group were (131.80±2.61), (93.87±1.00), (136.50±3.69), (105.70±0.84), (146.90±2.94), (105.00±2.25), (92.33±0.23), (88.63±0.31), (97.33±2.02), (81.77±1.33), (102.80±1.61), and (85.13±0.45) nmol/gProt, respectively, with statistically significant differences ( F=225.60, P<0.001; F=125.50, P<0.001) ; Compared with the untreated groups, the intracellular NADPH levels of HCT116 cells treated with BAY-876 was significantly decreased ( t=26.11, P<0.001; t=8.62, P<0.001; t=16.13, P<0.001; t=26.38, P<0.001; t=22.78, P<0.001; t=14.97, P<0.001). The fluorescence intensity of cystine in each group was 607.30±8.76, 655.70±6.57, 647.10±19.35, 737.80±6.34, 756.00±8.65, 846.60±11.70, 929.60±6.88, 1 049.00±22.35, 1 021.00±29.49, 1 094.00±16.17, 1 137.00±10.08, and 1 230.00±46.57, respectively, with statistically significant differences ( F=188.00, P<0.001; F=48.32, P<0.001). Compared with the untreated groups, the intracellular fluorescence intensity of cystine of HCT116 cells was significantly increased after treatment with BAY-876 ( t=50.09, P<0.001; t=29.26, P<0.001; t=18.34, P<0.001; t=35.53, P<0.001; t=49.66, P<0.001; t=13.83, P<0.001). The contents of cysteine in each group were (457.00±30.69), (581.20±30.69), (326.40±5.49), (374.20±5.54), (565.30±5.54), (246.80±30.69), (100.30±16.57), (472.90±19.10), (262.70±28.65), (348.70±9.55), (533.40±11.03), (30.23±5.49) μmol/L, respectively, with statistically significant differences ( F=110.00, P<0.001; F=423.50, P<0.001). Compared with the untreated groups, the intracellular contents of cysteine of HCT116 cells treated with BAY-876 was significantly decreased ( t=17.71, P<0.001; t=5.19, P=0.006; t=3.78, P=0.019; t=4.00, P=0.016; t=4.47, P=0.011; t=12.03, P<0.001) . Conclusion:Marsdenia tenacissima combined with XELOX solution can promote HCT116 cell death through disulfide apoptosis.

ObjectiveTo understand the use of antibiotics in inpatients and the incidence and trend of hospital infections， to explore the implementation effect of comprehensive management measures， and to provide reference for hospitals to use antibiotics reasonably. MethodsBased on the hospital infection monitoring and management system， a retrospective analysis and comparison were conducted on the use of antibiotics， submission of microbial test samples， and incidence of hospital infections among inpatients in a tertiary hospital from 2012 to 2021. ResultsFrom 2012 to 2021， the use of antibiotics showed a downward trend， from 50.82% in 2012 to 41.29% in 2021. At the same time， the use rate of restricted and special antibiotics had also decreased， and the use rate of restricted and special antibiotics in patients without hospital infection was significantly lower than that in patients with hospital infection， and the microbial testing rate was also on the rise. The annual incidence rate of hospital infection was 0.69%‒1.92%， and the annual case-time prevalence rate was 0.79%‒2.17%. The annual average rate of the above two in 10 years was 1.18% and 1.34%， respectively. The results of the exponential smoothing model also showed that the utilization rate of antibiotics was decreasing and the incidence of nosocomial infection was stable. ConclusionLarge general hospitals took comprehensive management measures to strengthen the management of rational use of antibiotics， which led to a decline in the use rate of antibacterial drugs for inpatients and an increase in the rate of microbial examination. At the same time， the overall incidence of hospital infection was relatively stable， suggesting that the comprehensive management measures of antibacterial drugs in hospitals had achieved certain results. The current measures need to be optimized in the future to continuously improve the management level of rational use of antibacterial drugs.

Objective:To construct a predictive nomogram incorporating pretreatment CT-based radiomics for radiation pneumonitis (RP) in esophageal cancer (EC) patients treated with intensity-modulated radiotherapy (IMRT), and to evaluate the value of CT radiomics in predicting RP.Methods:Clinical data of 267 EC patients sequentially treated with IMRT in Quanzhou First Hospital affiliated to Fujian Medical University from January 2019 to December 2021 were prospectively analyzed. Among them, the first 206 patients were assigned into the training cohort and the last 61 patients were enrolled in the validation cohort. Radiomics features of bilateral lungs were extracted by radiotherapy CT simulation. Univariate analysis was performed to screen the potential predictive variables for symptomatic RP. Machine learning algorithms, such as least absolute shrinkage and selection operator (LASSO), extreme gradient boosting (XGboost), and support vector machine (SVM), were performed for radiomic features selection, respectively. The best classifier was chosen to construct a radiomic signature (RS). Clinical, radiomics and combined nomogram predictive model were developed, respectively. The predictive efficiency and clinical benefits of three models were compared by calculating the area under the receiver operating characteristic (ROC) curve (AUC), calibration curve and decision curve analysis (DCA), and then validated in the validation cohort. Multivariate logistic regression analysis was conducted. Different ROC curves were compared by Delong test.Results:Cardiovascular disease, minimum internal diameter of esophagus and adjuvant chemotherapy and RS were the independent related factors of RP. The AUC of clinical, radiomics and combined models were 0.772, 0.745, 0.842 in the training cohort, and 0.851, 0.811, 0.901 in the validation cohort, respectively. DCA showed that combined radiomic model yielded better clinical benefits compared with clinical model.Conclusion:Radiomics features from pretreatment CT have the potential of improving the efficiency of RP prediction models for EC patients treated with IMRT.

Objective To evaluate the physical functions of community-dwelling older adults, and analyze the related factors. Methods From September to October, 2016, 80 adults over 55-year-old in one community in Wuhan, Hubei, China were selected with convenience sampling. General situation was collected through questionnaires. Physical functions were measured by tests of grip strength, Five-Times-Sit-to-Stand Test (FTSST), modified Clinical Test of Sensory Interaction and Balance (mCTSIB) and TimedUp and GoTest (TUGT). Their correlation was analyzed. Results The average grip strength of the participants was (27.46 ± 9.66) kg; the average time of FTSST was (11.58 ± 4.03) s;there was only one (1.25%) participant observed with an impairment in mCTSIB;the average time of TUGT was (9.05±3.47) s. Grip strength was correlated with gender (r=-0.669), education level (r=0.238), the score of Mini-Mental State Examina-tion (MMSE) (r=-0.302) and activities of daily living (ADL) (r=-0.344) (P<0.05). The time of FTSST was correlated to gender (r=0.274), the score of MMSE (r=0.243) and ADL (r=0.321) (P<0.05). The time of TUGT was correlated to gender (r=0.255), education level (r=-0.362), income level (r=-0.245), the score of Self-rating Depression Scale (r=0.223), the score of MMSE (r=0.328) and ADL (r=0.354) (P<0.05). Conclusion The levels of grip strength, FTSST and TUGT are related to the demographic characters in community-dwell-ing older adults. Little abnormity has been found in mCTSIB.